课题基金 / 基金详情

ANALYSIS OF CLASS II MHC DERIVED ANTIGENIC PEPTIDES FROM HUMAN INTESTINE

ANALYSIS OF CLASS II MHC DERIVED ANTIGENIC PEPTIDES FROM HUMAN INTESTINE
人肠 II 类 MHC 衍生抗原肽的分析
批准号:
09670565
负责人:
OSHITANI Nobuhide
金额:
$1.98万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 2000

项目摘要

项目成果

OSHITANI Nobuhide的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The specific antigen responsible for the pathogenesis of inflammatory bowel disease is unknown. We isolated HLA-DR-associated peptides from human intestine and sequenced their amino-acid residues by ion-trap tandem mass spectrometry equipped with online reverse-phase high performance liquid chromatography. Serum antibody titers against two of the above determined antigens were measured. We detected 73 parent proteins from 4 controls, 10 patients with ulcerative colitis, and 10 patients with Crohn's disease. The calculated molecular masses (m/z) of these peptides ranged from 582.2 to 2988.5, representing 7 to 27 amino acid residues. Sixty-eight of these 73 parent proteins were exogenous proteins. Neither MHC nor invariant chain-derived peptides were found among human intestinal class II MHC-associated peptides, contrary to previous findings for transformed cells. Escherichia coli-, Saccharomyces cerevisiae-, and Caenorhabditis elegans-derived peptides were found veryfrequently in patients with inflammatory bowel disease. Serum antibody titers against S.cerevisiae and C.elegans were measured, and were significantly higher in patients with inflammatory bowel disease than in controls. The present results suggest that in vivo antigen processing by antigen-presenting cells and T lymphocytes in human intestine are participated with exogenous antigen presentation. Increased immune responses against S.cerevisiae and C.elegans were found in patients with inflammatory bowel and may participate as dysregulated immune responses to enteric flora in the pathogenesis of inflammatory bowel disease.
期刊论文(25)
专著(0)
科研奖励(0)
会议论文
OSHITANI N. et al: "Down-regulation by bucillamine of lawina propria leukocytes in rat colitis model"Clin Exp Pharmacol Physiol. 26. 956-958 (1999)
OSHITANI N. 等人:“布西拉明对大鼠结肠炎模型中拉维纳固有白细胞的下调”Clin Exp Pharmacol Physiol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Oshitani N. et al: "Heterogeneity of HPLC Protiles of human class II MHC-bound peptides isolated from intestine with inflamatory bowal disease"Dig Dis Sci. (in press).
Oshitani N. 等人:“从患有炎症性肠病的肠道中分离出的人 II 类 MHC 结合肽的 HPLC 谱的异质性”Dig Dis Sci。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
OSHITANI.N etal: "Functional diversity of infiltrating macrophages in inflamed human colonic mucosa ulcerative colitis" Clin Exp Pharmacol Physiol. 25. 50-53 (1998)
OSHITANI.N 等人:“发炎的人结肠粘膜溃疡性结肠炎中浸润巨噬细胞的功能多样性”Clin Exp Pharmacol Physiol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
OSHITANI N. et al: "Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease"J Gastroenterol Hepatol. 15. 1400-1403 (2000)
OSHITANI N. 等人:“美沙拉秦可降低克罗恩病患者的抗酿酒酵母抗体滴度”J Gastroenterol Hepatol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
23
    Tight junction proteins in inflammatory bowel disease
    • 批准号:
      18590695
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.45万
    • 财政年份:
      2006
    • 负责人:
      OSHITANI Nobuhide
    • 依托单位:
    Role of class II MHC bound antigenic peptide in the pathogenesis of inflammatory bowel disease.
    • 批准号:
      15590676
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.98万
    • 财政年份:
      2003
    • 负责人:
      OSHITANI Nobuhide
    • 依托单位:
    国内基金
    海外基金
    基于单细胞测序探讨气道上皮细胞HLA-DR分子在吸烟诱导的气道过度炎症中的作用机制
    • 批准号:
      82370021
    • 项目类别:
      面上项目
    • 资助金额:
      49万元
    • 批准年份:
      2023
    • 负责人:
      易群
    • 依托单位:
    肺炎克雷伯菌FimA抗原的HLA-DR限制性Th17细胞优势应答谱学特征与疾病转归相关性研究
    新冠病毒表位的HLA-DR限制性Th优势应答谱学特征及其与疾病转归相关性研究
    乙肝恶性转化中HLA-DR基因多态性和T细胞受体库多样性的联合作用机制
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      邓阳
    • 依托单位: